TY - JOUR
T1 - Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy
AU - Hoff, Paulo M.
AU - Valero, Vicente
AU - Buzdar, Aman U.
AU - Singletary, S. Eva
AU - Theriault, Richard L.
AU - Booser, Daniel
AU - Asmar, Lina
AU - Frye, Debra
AU - McNeese, Marsha D.
AU - Hortobagyi, Gabriel N.
N1 - Funding Information:
Du Min, Liu Min, Liu Jue Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Corresponding author: Liu Jue, Email: jueliu@bjmu.edu.cn 【Abstract】 SARS-CoV-2 Delta variant has the characteristics of stronger infectivity, higher viral load, and shorter incubation period, posing new challenges to the prevention and control of COVID-19 pandemic. SARS-CoV-2 Delta variant was first discovered in India, then quickly spread in many countries and has gradually become one of the main epidemic strains worldwide. Local epidemics caused by SARS-CoV-2 Delta variant also occurred in several provinces in China. This article summarizes the progress in research of etiological characteristics, transmission characteristics or possible mechanism and epidemiological characteristics of SARS-CoV-2 Delta variant, and the protective effects of vaccines and control measures against SARS-CoV-2 Delta variant in order to provide references for the effective prevention and control of COVID-19 epidemic caused by SARS-CoV-2 Delta variant. 【Key words】 SARS-CoV-2; Delta variants of concern; Epidemiology; Review Fund program: National Natural Science Foundation of China (72122001, 71934002); National Key Research and Development Project of China (2020YFC0846300, 2020YFC0849500)
PY - 2000/5/1
Y1 - 2000/5/1
N2 - BACKGROUND. The purpose of the current study was to evaluate the objective response rate and possibility of breast-conserving surgery using neoadjuvant tamoxifen in the multimodality treatment, including surgery and radiotherapy, of elderly or frail patients with locally advanced breast carcinoma. METHODS. Forty-seven patients age > 75 years or age < 75 years with comorbid conditions and locally advanced breast carcinoma were treated with neoadjuvant tamoxifen (20 mg/day) for 3-6 months. This was followed by surgery and radiotherapy when feasible and adjuvant tamoxifen for 5 years or until disease recurrence. RESULTS. The median age of the patients was 72 years (range, 48-86 years). Approximately 22% had T3 lesions, 57% had T4 lesions, 22% were Stage II (AJCC Manual for Staging Cancer, 3rd edition), and 78% were Stage III. Eighty percent were estrogen receptor positive. After 6 months of treatment with neoadjuvant tamoxifen, a response rate of 47% was observed, including a complete response rate of 6%. Twenty-nine patients (62%) were rendered free of disease by surgery, including 5 with breast- conserving procedures. After a median follow-up of 40 months, 23 patients (49%) remained disease free. The median survival time had not been reached at the time of last follow-up. No major toxicity was observed, with the exception of one patient who developed a possible tamoxifen-related Stage I endometrial carcinoma. The estimated 2-year and 5-year progression free and overall survival rates were 50% and 41%, and 83% and 59%, respectively. CONCLUSIONS. The results of the current study show that neoadjuvant tamoxifen was effective in the treatment of elderly or frail patients with locally advanced breast carcinoma with estrogen receptor positive tumors, and resulted in a reasonable response rate, including complete responses and good overall survival. (C) 2000 American Cancer Society.
AB - BACKGROUND. The purpose of the current study was to evaluate the objective response rate and possibility of breast-conserving surgery using neoadjuvant tamoxifen in the multimodality treatment, including surgery and radiotherapy, of elderly or frail patients with locally advanced breast carcinoma. METHODS. Forty-seven patients age > 75 years or age < 75 years with comorbid conditions and locally advanced breast carcinoma were treated with neoadjuvant tamoxifen (20 mg/day) for 3-6 months. This was followed by surgery and radiotherapy when feasible and adjuvant tamoxifen for 5 years or until disease recurrence. RESULTS. The median age of the patients was 72 years (range, 48-86 years). Approximately 22% had T3 lesions, 57% had T4 lesions, 22% were Stage II (AJCC Manual for Staging Cancer, 3rd edition), and 78% were Stage III. Eighty percent were estrogen receptor positive. After 6 months of treatment with neoadjuvant tamoxifen, a response rate of 47% was observed, including a complete response rate of 6%. Twenty-nine patients (62%) were rendered free of disease by surgery, including 5 with breast- conserving procedures. After a median follow-up of 40 months, 23 patients (49%) remained disease free. The median survival time had not been reached at the time of last follow-up. No major toxicity was observed, with the exception of one patient who developed a possible tamoxifen-related Stage I endometrial carcinoma. The estimated 2-year and 5-year progression free and overall survival rates were 50% and 41%, and 83% and 59%, respectively. CONCLUSIONS. The results of the current study show that neoadjuvant tamoxifen was effective in the treatment of elderly or frail patients with locally advanced breast carcinoma with estrogen receptor positive tumors, and resulted in a reasonable response rate, including complete responses and good overall survival. (C) 2000 American Cancer Society.
KW - Locally advanced breast carcinoma
KW - Multimodality treatment
KW - Neoadjuvant
KW - Tamoxifen
UR - http://www.scopus.com/inward/record.url?scp=0034192182&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034192182&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0142(20000501)88:9<2054::AID-CNCR11>3.0.CO;2-J
DO - 10.1002/(SICI)1097-0142(20000501)88:9<2054::AID-CNCR11>3.0.CO;2-J
M3 - Article
C2 - 10813717
AN - SCOPUS:0034192182
SN - 0008-543X
VL - 88
SP - 2054
EP - 2060
JO - Cancer
JF - Cancer
IS - 9
ER -